Pharma Groups Fight Proposed Ban On Titanium Dioxide In Europe

Amsterdam: Pharmaceutical industry groups are working to submit comments to the European Medicines Agency (EMA) to oppose a proposed ban on the use of titanium dioxide (TiO2) in Europe. The European Commission is expected to make a final decision on the ban in February 2025, which if enacted would take effect in early 2026.

These actions were prompted by a scientific opinion from the European Food Safety Authority (EFSA) in May 2021 that concluded that TiO2 (also known as E 171) is not considered safe when used as a food additive. Shortly after, in January 2022, the European Commission published a regulation removing the authorization for TiO2 as a food additive and opening up the possibility of extending the ban to pharmaceuticals.

Experts recently described to Focus some of the behind-the-scenes discussions about addressing this ban and reiterated concerns on the high cost of reformulating drugs with TiO2-free alternatives. They also stated that European regulators’ concerns about TiO2 in food and pharmaceuticals is not shared by other health authorities.

The Commission, in its 2022 regulation, said it would “review the necessity to maintain titanium dioxide (E 171) or otherwise delete it from the Union list of food additives for exclusive use as a colour in medicinal products within three years.” The review will be informed by an assessment by the European Medicines Agency (EMA) that is expected to be completed by 1 April 2024.

At this year’s Excipient World conference in National Harbor, MD, panelists said that the ban would have a grave impact and lead to drug shortages.

Looking at the big picture, Hughes said the EFSA 2021 opinion lacked a scientific justification to support the ban. “When you look at it, the EFSA opinion 2021, it did not identify any specific safety issues. There was a lack of data around genotoxicity. They could not prove it was harmful, but they could not prove it was safe,” he said.

As such, the European Commission invoked the “precautionary principle” and proposed to ban the ingredient altogether rather than risk its continued use in pharmaceuticals, Hughes explained. He added that other regulators, including the UK and Japan “disagreed with the EFSA report. They disagreed with the conclusions and the precautionary approach that the EU used.”

Canada, Australia, New Zealand and the US have stated that TiO2 as a food additive does not pose a risk to human health, according to Hughes.

Schoneker agreed that the European Commission is an outlier in this area. “The bottom line is that there is no scientific explanation to support the ban, it is a farce,” he said. “There is absolutely no scientific justification for them taking this position,” he said.

Schoneker added that European regulators are unnecessarily scaring the public. “The Japanese conducted a similar study and found no safety problems with TiO2,” he said.

Related Posts

  • Pharma
  • July 16, 2025
  • 151 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 48 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Famous Vaidyaratnam Ayurveda Clinic in Delhi is now more Accessible to Patients

Famous Vaidyaratnam  Ayurveda  Clinic in Delhi is now more Accessible to Patients